BTIS
RARE icon

BB&T Investment Services’s Ultragenyx Pharmaceutical RARE Stock Holding History

BB&T Investment Services’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$1K Hold
30
– – ﹤0.01% 1368
2017
Q3 		$2K Buy
+30
New +$1.78K ﹤0.01% 1119

Other funds holding RARE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BB&T Investment Services's RARE Position: Q4 2017 in Review

BB&T Investment Services held its Ultragenyx Pharmaceutical (RARE) position steady in Q4 2017 at 30 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #1368.

BB&T Investment Services first reported a position in RARE in Q3 2017 and has held it in 2 quarters since. The position peaked at $2K in Q3 2017. 163 funds tracked by Wall St. Rank hold RARE as of Q4 2017.

  • BB&T Investment Services held 30 shares of Ultragenyx Pharmaceutical worth $1K as of Q4 2017.
  • BB&T Investment Services left its Ultragenyx Pharmaceutical share count unchanged in Q4 2017.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of BB&T Investment Services's portfolio in Q4 2017, its #1368 holding.
  • BB&T Investment Services first reported a position in Ultragenyx Pharmaceutical in Q3 2017 and has held it in 2 quarters since.
  • BB&T Investment Services's Ultragenyx Pharmaceutical position peaked at $2K in Q3 2017.
  • 163 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2017.

Based on BB&T Investment Services's 13F filing for Q4 2017, filed 15 Feb 2018.